Skip to main content
Fig. 10 | Journal of Nanobiotechnology

Fig. 10

From: CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling

Fig. 10

In vivo antitumor efficacy and reprogramming of TME. (A) Photographs of tumor formed by B16F10 and CAFs after four treatments. (B) Changes of tumor volume during the treatment (n = 5) **p < 0.001(t-test). (C) Weight of tumors formed by B16F10 and CAFs after four treatments (n = 5). (D) H&E staining. Scale bar: 200 μm. (E) Ki67 staining. Scale bar: 200 μm. (F) Tunel staining. Scale bar: 200 μm. (G) Masson trichrome staining. Scale bar: 200 μm. (H) IHC staining of α-SMA. Scale bar: 200 μm. (I) IHC staining of GLUL. Scale bar: 200 μm. (J) Ki67 index analysis (n = 3). (K) Quantitative analysis of Tunel positive cells (n = 3). (L) Analysis of positive area of Masson (n = 3). (M) Quantitative analysis of α-SMA (n = 3). (N) Analysis of positive area of GLUL (n = 3). * p < 0.05, ** p < 0.01, and *** p < 0.001 (ANOVA test). All statistical data are expressed as means ± SD (n = 5). G1, Control; G2, FH-siGLUL-NDs; G3, FH-V9302-NDs; G4, Free V9302; G5, FH-V9302-siGLUL-NDs; G6, V9302-siGLUL-NDs + US; and G7, FH-V9302-siGLUL-NDs + US

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us